Edgewise Therapeutics Inc’s filing revealed that its Director Thompson Peter A. acquired Company’s shares for reported $10.0 million on Apr 03 ’25. In the deal valued at $20.13 per share,496,771 shares were bought. As a result of this transaction, Thompson Peter A. now holds 14,809,075 shares worth roughly $199.18 million.
Then, ORBIMED ADVISORS LLC bought 496,771 shares, generating $10,000,000 in total proceeds. Upon buying the shares at $20.13, the Director now owns 14,809,075 shares.
Before that, Russell Alan J sold 200 shares. Edgewise Therapeutics Inc shares valued at $6,004 were divested by the Chief Scientific Officer at a price of $30.02 per share. As a result of the transaction, Russell Alan J now holds 14,863 shares, worth roughly $0.2 million.
Scotiabank downgraded its Edgewise Therapeutics Inc [EWTX] rating to a Sector perform from a a Sector outperform in a research note published recently. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in early March with a ‘”a Sector outperform”‘ rating. Stifel began covering EWTX with “Hold” recommendation on January 22, 2025. Evercore ISI started covering the stock on November 22, 2024. It rated EWTX as “an Outperform”.
Price Performance Review of EWTX
On Thursday, Edgewise Therapeutics Inc [NASDAQ:EWTX] saw its stock jump 3.22% to $13.45. Over the last five days, the stock has gained 16.25%. Edgewise Therapeutics Inc shares have fallen nearly -49.63% since the year began. Nevertheless, the stocks have fallen -19.12% over the past one year. While a 52-week high of $38.12 was reached on 02/06/25, a 52-week low of $10.60 was recorded on 04/07/25. SMA at 50 days reached $22.35, while 200 days put it at $25.18.
Levels Of Support And Resistance For EWTX Stock
The 24-hour chart illustrates a support level at 12.85, which if violated will result in even more drops to 12.25. On the upside, there is a resistance level at 13.81. A further resistance level may holdings at 14.18. The Relative Strength Index (RSI) on the 14-day chart is 32.10, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.65, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 77.24%. Stochastics %K at 19.34% indicates the stock is a buying.
How much short interest is there in Edgewise Therapeutics Inc?
A steep rise in short interest was recorded in Edgewise Therapeutics Inc stocks on 2025-03-31, growing by 1.65 million shares to a total of 10.39 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 8.73 million shares. There was a rise of 15.93%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 07, 2024 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $48 price target.
